STOCK TITAN
  1. Home
  2. Sec-filings
  3. RADX
  4. [6-K] Radiopharm Theranostics Ltd Current Report (Foreign Issuer)

Radiopharm investors approve new share and warrant issues

Radiopharm Theranostics Limited (RADX) reports that shareholders at a General Meeting on September 11, 2026 approved all resolutions by poll.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Radiopharm Theranostics Limited (RADX) reports that shareholders at a General Meeting on September 11, 2026 approved all resolutions by poll. The resolutions ratified prior issues of First Tranche placement shares and ADS shares, and approved the issue of Second Tranche placement shares, placement attaching options, SPP shares and SPP attaching options, shortfall options, ADR warrants and agent warrants.

Shareholders also approved issues of SPP shares and attaching options to directors Paul Hopper, Ian Turner and Bruce Goodwin, and to Chief Executive Officer and director Riccardo Canevari. Support across all resolutions was high, with poll results generally showing more than 94% of votes cast in favor of each proposal.

Positive

  • None.

Negative

  • None.
Resolution 1a poll votes for 1,189,341,842 votes (97.33%) Poll votes for ratification of prior issue of First Tranche Placement Shares
Resolution 1a poll votes against 32,644,514 votes (2.67%) Poll votes against ratification of prior issue of First Tranche Placement Shares
Resolution 2 poll votes for 1,181,810,909 votes (96.81%) Poll votes for approval to issue Second Tranche Placement Shares
Resolution 5 poll votes for 1,178,944,225 votes (96.58%) Poll votes for approval to issue Shortfall Options
Resolution 7 poll votes for 1,179,865,854 votes (95.77%) Poll votes for approval to issue Agent Warrants
Resolution 8d poll votes for 1,064,818,860 votes (95.16%) Poll votes for approval to issue SPP Shares and SPP Attaching Options to CEO and director Riccardo Canevari
Resolution 8d poll votes against 54,129,668 votes (4.84%) Poll votes against issue of SPP Shares and SPP Attaching Options to CEO and director Riccardo Canevari
ASX Listing Rule 3.13.2 regulatory
"In accordance with ASX Listing Rule 3.13.2 and Section 251AA(1)"
Corporations Act 2001 regulatory
"In accordance with ASX Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001"
The Corporations Act 2001 is Australia’s primary law that sets the rules for creating, operating and regulating companies, covering directors’ duties, financial reporting, required disclosures and takeover and insolvency procedures. For investors it acts like a rulebook and referee, making companies provide reliable financial information, follow governance standards and protect shareholder rights — which helps reduce fraud and makes investment choices more dependable.
Shortfall Options financial
"5 Approval to issue Shortfall Options"
ADR Warrants financial
"6 Approval to issue ADR Warrants"
SPP Shares financial
"4a Approval to issue SPP Shares to Eligible Shareholders"
SPP Attaching Options financial
"4b Approval to issue SPP Attaching Options to Eligible Shareholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Radiopharm Theranostics (RADX) announce in the September 2026 Form 6-K?
Radiopharm Theranostics reported that at its General Meeting on September 11, 2026, all resolutions put to shareholders were carried by poll. The resolutions mainly concerned ratifying prior share issues and approving issues of additional shares, options, and warrants.

Were all resolutions at RADX’s September 11, 2026 General Meeting approved?
Yes. Radiopharm Theranostics states that all resolutions considered at the General Meeting held on September 11, 2026 were carried by poll, with detailed proxy and poll voting results provided for each item.

How strong was shareholder support for key resolutions at RADX’s meeting?
Support was high. For example, Resolution 1a had 97.33% of poll votes in favor, Resolution 2 had 96.81% in favor, and director-related Resolution 8d received 95.16% of poll votes for, indicating broad approval of the proposals.

Were equity grants to Radiopharm Theranostics directors and CEO approved?
Yes. Resolutions 8a–8d approving issues of SPP Shares and SPP Attaching Options to directors Paul Hopper, Ian Turner, Bruce Goodwin, and to Chief Executive Officer and director Riccardo Canevari were all carried with poll support of just over 95% in favor.

What voting framework governed RADX’s General Meeting results disclosure?
Radiopharm Theranostics states that the voting details were provided in accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, including proxy votes, poll results for and against, abstentions, and outcomes for each resolution.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of September 2026

 

Commission File Number: 001-41621

 

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

 

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

 

 

 

RADIOPHARM THERANOSTICS LIMITED

 

EXPLANATORY NOTE

 

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on September 11, 2026 titled:

 

“Results of Meeting”

 

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

 

This report on Form 6-K (including any exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any registration statement or prospectus under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such registration statement or prospectus.

 

1

 

EXHIBITS

 

Exhibit
Number		   Description
99.1   Results of Meeting

 

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  RADIOPHARM THERANOSTICS LIMITED
     
Date: September 11, 2026 By: /s/ Amritha Sushil
    Amritha Sushil
    Company Secretary

 

3

Exhibit 99.1

 

ASX ANNOUNCEMENT
11 September 2026

 

Results of General Meeting

 

Sydney, Australia – Friday, 11 September 2026 – Radiopharm Theranostics Limited (ASX: RAD; Nasdaq: RADX) advises that all resolutions considered at the General Meeting held today were carried by poll.

 

In accordance with ASX Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, details of the proxies received and votes cast in respect of each resolution are attached.

 

Amritha Sushil

Joint Company Secretary

 

Radiopharm Theranostics Limited

Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia

ABN: 57 647 877 889

 

 

 

Disclosure of Proxy Votes

Radiopharm Theranostics Limited

Extraordinary General Meeting

Friday, 11 September 2026

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814 

 

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

 

   Proxy Votes  Poll Results (if applicable)  Results 
Resolution  Decided by Show of Hands (S) or Poll (P)  Total Number of Proxy Votes exercisable by proxies validly appointed   FOR  AGAINST   ABSTAIN   PROXY'S DISCRETION  FOR  AGAINST   ABSTAIN   OUTCOME 
1a Ratification of prior issue of First Tranche Placement Shares to Placement Participants   P   1,221,986,356   1,187,939,605
97.21%		   

32,644,514

2.67%

    12,057,450   1,402,237
0.11%		  1,189,341,842
97.33%		   

32,644,514

2.67%

    12,057,450    

 

Carried

 
1b Ratification of prior issue of ADS Shares to US Participants   P   1,221,353,323   1,212,284,305
99.26%		   

8,900,114

0.73%

    12,690,483   168,904
0.01%		  1,212,453,209
99.27%		   

8,900,114

0.73%

    12,690,483    

 

Carried

 
2 Approval to issue Second Tranche Placement Shares to Placement Participants   P   1,220,753,023   1,181,642,005
96.80%		   

38,942,114

3.19%

    13,290,783   168,904
0.01%		  1,181,810,909
96.81%		   

38,942,114

3.19%

    13,290,783    

 

Carried

 
3 Approval to issue Placement Attaching Options to Placement Participants   P   1,221,353,023   1,179,718,821
96.59%		   

41,465,298

3.40%

    12,690,783   168,904
0.01%		  1,179,887,725
96.60%		   

41,465,298

3.40%

    12,690,783    

 

Carried

 
4a Approval to issue SPP Shares to Eligible Shareholders   P   1,222,586,656   1,183,318,738
96.79%		   

39,099,014

3.20%

    11,457,150   168,904
0.01%		  1,183,487,642
96.80%		   

39,099,014

3.20%

    11,457,150    

 

Carried

 
4b Approval to issue SPP Attaching Options to Eligible Shareholders   P   1,221,926,656   1,180,363,554
96.60%		   

41,394,198

3.39%

    12,117,150   168,904
0.01%		  1,180,532,458
96.61%		   

41,394,198

3.39%

    12,117,150    

 

Carried

 
5 Approval to issue Shortfall Options   P   1,220,693,323   1,178,775,321
96.57%		   

41,749,098

3.42%

    13,350,483   168,904
0.01%		  1,178,944,225
96.58%		   

41,749,098

3.42%

    13,350,483    

 

Carried

 

 

 

2

 

 

   Proxy Votes  Poll Results (if applicable)  Results 
Resolution  Decided by Show of Hands (S) or Poll (P)  Total Number of Proxy Votes exercisable by proxies validly appointed   FOR  AGAINST   ABSTAIN   PROXY'S DISCRETION  FOR  AGAINST   ABSTAIN   OUTCOME 
6 Approval to issue ADR Warrants   P   1,221,353,023   1,179,696,950
96.59%		   

41,487,169

3.40%

    12,690,783   168,904
0.01%		  1,179,865,854
96.60%		   

41,487,169

3.40%

    12,690,783    

 

Carried

 
7 Approval to issue Agent Warrants   P   1,231,979,023   1,179,696,950
95.76%		   

52,113,169

4.23%

    2,064,783   168,904
0.01%		  1,179,865,854
95.77%		   

52,113,169

4.23%

    2,064,783    

 

Carried

 
8a Approval to issue SPP Shares and SPP Attaching Options to Director, Paul Hopper   P   948,869,958   894,216,556
94.24%		   

54,461,314

5.74%

    285,173,848   192,088
0.02%		  894,408,644
94.26%		   

54,461,314

5.74%

    285,173,848    

 

Carried

 
8b Approval to issue SPP Shares and SPP Attaching Options to Director, Ian Turner   P   1,116,328,635   1,062,156,879
95.15%		   

53,979,668

4.84%

    117,715,171   192,088
0.02%		  1,062,348,967
95.16%		   

53,979,668

4.84%

    117,715,171    

 

Carried

 
8c Approval to issue SPP Shares and SPP Attaching Options to Director, Bruce Goodwin   P   1,118,859,230   1,064,537,474
95.14%		   

54,129,668

4.84%

    115,184,576   192,088
0.02%		  1,064,729,562
95.16%		   

54,129,668

4.84%

    115,184,576    

 

Carried

 
8d Approval to issue SPP Shares and SPP Attaching Options to Chief Executive Officer and Director Riccardo Canevari   P   1,118,948,528   1,064,626,772
95.15%		   

54,129,668

4.84%

    115,095,278   192,088
0.02%		  1,064,818,860
95.16%		   

54,129,668

4.84%

    115,095,278    

 

Carried

 

 

 

3

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases

Keep reading

More on RADX

Trending in the feed

Open the live feed